![]() |
市场调查报告书
商品编码
1727692
基因的共同研究及授权契约:2018年~2025年Genomic Collaboration and Licensing Deals 2018-2025 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
"基因组合作与授权协议" 提供了前所未有的途径,让我们能够全面了解世界领先生物製药公司达成的基因组协议。
本报告经过全面修订和更新,提供了 2018 年至 2025 年基因组交易的详细资讯。它详细了解并分析了公司达成基因组交易的方式和原因。这些交易通常涉及多个环节,从合作研发开始,到成果商业化结束。
本报告涵盖合作、开发、研究和授权交易。
本报告包含自 2018 年以来宣布的 639 项基因组交易的完整列表,包括财务条款(如有),以及交易方披露的实际基因组合作交易的在线交易记录链接。此外,报告还收录了公司及其合作伙伴向美国证券交易委员会提交的合约文件(如有)。
本报告第一章介绍了基因组学交易。
第一章是对报告的介绍。
第二章概述了自2018年以来的基因组学交易趋势。
第三章概述了自2018年以来的主要基因组学交易。交易按交易金额排序。
第四章列出了在基因组学交易中最活跃的25家公司,并附有简要摘要,随后是基因组学交易的完整列表以及公开的合约文件。
第五章对自2018年1月以来签署和宣布的基因组学交易进行了全面深入的回顾,合约文件已公开发布。
第六章全面深入地回顾了自2018年1月以来签署和宣布的基因组学合作交易。本章按感兴趣的特定基因组学技术类型进行组织。
报告还包含大量图表,展示了自2018年以来基因组学交易的趋势和活动。
此外,综合交易目录按公司A-Z、交易类型和治疗目标进行组织。每个交易标题都透过网页连结连结到线上交易记录,并包含合约文件(如有),方便您随时存取每份交易文件。
基因体学合作与授权交易提供读者以下主要优势:
基因体学合作与授权协议包括:
分析合约文件有助于进行尽职调查:
Genomic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genomic deals entered into by the world's leading biopharma companies.
Fully revised and updated, the report provides details of genomic deals from 2018 to 2025.
The report provides a detailed understanding and analysis of how and why companies enter genomic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 639 genomic deals announced since 2018 including financial terms where available including links to online deal records of actual genomic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of genomic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in genomic dealmaking since 2018.
Chapter 3 provides an overview of the leading genomic deals since 2018. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomic dealmaking with a brief summary followed by a comprehensive listing of genomic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of genomic deals signed and announced since Jan 2018, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of genomic partnering deals signed and announced since Jan 2018. The chapter is organized by specific genomic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in genomic deal making since 2018.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Genomic Collaboration and Licensing Deals provides the reader with the following key benefits:
Genomic Collaboration and Licensing Deals includes:
Analyzing contract agreements allows due diligence of: